Genome Editing

Selected news for the healthcare topic - Genome Editing, collected since 10/2017. Recent stories appear in ddw-online.com and genengnews.com. This healthcare topic shares news with CRISPR, Sangamo Therapeutics, Precision BioSciences, Biotech, Intellia Therapeutics and over a hundred others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
2/23/2021 ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement – Drug Discovery World (DDW) ddw-online.com ... holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize ...
2/23/2021 Preclinical Study Shows Safety, Efficacy, and Durability of Lowering LDL-Cholesterol Levels Long-Term in Non-Human Primates genengnews.com ... announced the publication of preclinical data of a three-year follow-up study showing long-term, stable reduction of LDL-c levels in nonhuman primates (NHPs) through gene silencing using their proprietary ARCUS ® genome editing platform.The study, “ Long-term Stable Reduction of Low-density Lipoprotein in Nonhuman Primates Following In Vivo Genome Editing of PCSK9 ” published in Molecular Therapy , was led by James M. Wilson, MD ...
2/23/2021 JDRF Announces New Center of Excellence in New England to Advance Type 1 Diabetes Research PR Newswire ... and Stephan Kissler , Ph.D., at Joslin Diabetes Center. The team will closely collaborate with Lenny Shultz , Ph.D., at The Jackson Laboratory in Maine ."By taking advantage of the advances in stem cell science and genome editing , our team is excited to work collaboratively to solve the problem of immune rejection of beta cells," said Dr. Melton, who is the Xander University Professor of Stem Cell and Regenerative Biology at Harvard ...
2/23/2021 Genome Editing Market Size, Share, Growth, Sales and Drivers Analysis Research Report 2027 heraldkeeper.com ... line engineering, which enables the development of next generation’s therapies and drugs. However, the agricultural industry has seen more success with gene editing techniques largely due to the less stringent regulatory environment.Global Genome Editing Market is expected to exceed more than US$ 7.5 billion by 2024 at CAGR of 14% in the given forecast period.The global genome editing market is rapidly increasing due to the increased government ...
2/23/2021 ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement Yahoo News ... holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform."G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool," said Eric Rhodes, CEO of ERS Genomics. "We are pleased to provide access to this Nobel Prize winning ...
2/23/2021 ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement Business Wire ... holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize ...
2/23/2021 malvern-online.com ... holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize ...
2/22/2021 The Path to Better Health: Give People Their Data issues.org ... treatments for disease, it’s getting patients to do the things we already know work—exercising, quitting smoking, eating right, and taking medications regularly. Despite astounding success in highly technical areas such as immunotherapy, genome editing , and surgical robotics, medicine has been unable to solve the most basic challenge of helping patients make good decisions for themselves. This challenge lies at the heart of the nation’s most pervasive health ...
2/22/2021 Financial Survey: Editas Medicine (NASDAQ:EDIT) vs. AlloVir (NASDAQ:ALVR) thelincolnianonline.com AlloVir beats Editas Medicine on 7 of the 9 factors compared between the two stocks.About Editas MedicineEditas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR ...
2/22/2021 Tweaking corn kernels with CRISPR cshl.edu Home / Newsstand / CSHL Stories and Media Tweaking corn kernels with CRISPR Stem cell growth, required for kernel development, is controlled in corn by a set of genes called CLEs. But how these genes change the corn is complicated. Using CRISPR genome editing , CSHL researchers found they could change kernel yield and ear size by fine-tuning the activity of one of the CLE genes, ZmCLE7 . In the image: an unmodified ...
2/20/2021 CRISPR people : the science and ethics of editing humans Stanford Includes bibliographical references and index Contents Just what did He Jiankui do? Human germline genome editing : what is it? CRISPR : what is it and why is it important Ethics discussion of CRISPR'd babies before He The law of CRISPR'd babies before He The He experiment revealed The world reacts--and so does China Who knew what when? : revelations of pre-summit knowledge Assessing the He experiment Is human germline genome ...
2/19/2021 Precision's one-time gene editing treatment lowers cholesterol in monkeys for 3 years FierceBiotech ... an alternative to fighting heart disease with PCSK9-lowering drugs like Amgen’s Repatha as well as Sanofi and Regeneron’s Praluent, researchers said. (Pixabay)Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the approach—designed as a one-time treatment—holds promise for treating familial hypercholesterolemia, high ...
2/19/2021 FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS) thailandmirror.com ... functional combination of skill sets and expertise will help to advance FAST’s deep funding strategies, while leveraging these learnings to other NDDs.“The emergence of novel therapeutic platforms such as gene therapy and genome editing has created exciting opportunities for possible treatments for neurodevelopmental disorders. INSYNC-AS will be a great way to help the Angelman syndrome community assess, and potentially direct, these technologies to therapies,” said James ...
2/19/2021 FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS) singaporenewsgazette.com ... functional combination of skill sets and expertise will help to advance FAST’s deep funding strategies, while leveraging these learnings to other NDDs.“The emergence of novel therapeutic platforms such as gene therapy and genome editing has created exciting opportunities for possible treatments for neurodevelopmental disorders. INSYNC-AS will be a great way to help the Angelman syndrome community assess, and potentially direct, these technologies to therapies,” said James ...
2/19/2021 FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS) malaysianewsgazette.com ... functional combination of skill sets and expertise will help to advance FAST’s deep funding strategies, while leveraging these learnings to other NDDs.“The emergence of novel therapeutic platforms such as gene therapy and genome editing has created exciting opportunities for possible treatments for neurodevelopmental disorders. INSYNC-AS will be a great way to help the Angelman syndrome community assess, and potentially direct, these technologies to therapies,” said James ...
2/18/2021 Genome Engineering Market Size, Share, Trends - Analysis Report 2022 PRSync ... 6.28 billion by 2022 from USD 3.19 billion in 2017, at a CAGR of 14.5% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000 The key factors propelling the growth of this genome editing market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.In ...
2/18/2021 The Ridgway Record ridgwayrecord.com Newark, NJ, As per the report published by Fior Markets, the global genome editing market is expected to grow from USD 5.37 billion in 2020 to USD 17.36 billion by 2028, at a CAGR of 15.8% during the forecast period 2021-2028.Some of the factors that drive the growth of the global genome editing market are expanding genetic research funding in North America, rising synthetic gene demand in North America ...
2/18/2021 Global Genome Editing Market Is Expected to Reach USD 17.36 Billion by 2028 : Fior Markets Globe Newswire Newark, NJ, As per the report published by Fior Markets, the global genome editing market is expected to grow from USD 5.37 billion in 2020 to USD 17.36 billion by 2028, at a CAGR of 15.8% during the forecast period 2021-2028.Some of the factors that drive the growth of the global genome editing market are expanding genetic research funding in North America, rising synthetic gene demand in North America ...
2/17/2021 Genome Editing/Genome Engineering Market Outlook 2020: Growth Factors Details, Trends, Comprehensive Research Including Top Companies aeresearch.net The latest Genome Editing /Genome Engineering market report is a rich resource of top line data and analysis of factors driving the growth of this business sphere. It also encompasses a multitude of risk-averting plans to help businesses indulge themselves in opportunities that can turn in strong profits in the upcoming years. Moreover, the report encompasses verifiable projections for the market its and its sub-markets based on the ...
2/16/2021 Genomics Market Expanding Growth 13.65% by 2030 Wordpress.com ... a certain degree, restrict market development. The key tool for the creation of successful therapies is genomic research, a primary reason why many government agencies are investing in a genome project. Traditional techniques of genome editing are time-consuming, costly, and labor-intensive and have a limited ability to keep pace with the age of rapidly advancing genome modification. However, by enabling quick and accurate genome editing , the advent of ...